RXO (NYSE:RXO – Get Free Report) is scheduled to be releasing its earnings data before the market opens on Thursday, November 7th. Analysts expect RXO to post earnings of $0.05 per share for the quarter. Individual interested in participating in the company’s earnings conference call can do so using this link.
RXO (NYSE:RXO – Get Free Report) last announced its quarterly earnings data on Wednesday, August 7th. The company reported $0.03 earnings per share (EPS) for the quarter, meeting analysts’ consensus estimates of $0.03. The firm had revenue of $930.00 million during the quarter, compared to the consensus estimate of $934.14 million. RXO had a positive return on equity of 2.22% and a negative net margin of 0.55%. The business’s revenue for the quarter was down 3.4% on a year-over-year basis. During the same quarter in the prior year, the company earned $0.08 EPS. On average, analysts expect RXO to post $0 EPS for the current fiscal year and $1 EPS for the next fiscal year.
RXO Trading Up 0.1 %
NYSE RXO opened at $27.95 on Tuesday. The business’s fifty day moving average is $27.75 and its 200-day moving average is $25.55. The company has a debt-to-equity ratio of 0.64, a current ratio of 1.17 and a quick ratio of 1.17. The stock has a market capitalization of $4.49 billion, a price-to-earnings ratio of -155.28, a PEG ratio of 12.29 and a beta of 1.33. RXO has a one year low of $17.17 and a one year high of $32.82.
Analysts Set New Price Targets
Check Out Our Latest Stock Analysis on RXO
About RXO
RXO, Inc provides full truckload freight transportation brokering services. It also offers brokered services for managed transportation, last mile, and freight forwarding. The company was incorporated in 2022 and is based in Charlotte, North Carolina.
Featured Articles
- Five stocks we like better than RXO
- How to Buy Cheap Stocks Step by Step
- Intel: Is Now the Time to Be Brave?Â
- Dividend Payout Ratio Calculator
- Carnival or Royal Caribbean—Which Cruise Stock Has More Upside?
- What Does Downgrade Mean in Investing?
- Summit Therapeutics: Is Their Lung Cancer Drug a Game Changer?
Receive News & Ratings for RXO Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for RXO and related companies with MarketBeat.com's FREE daily email newsletter.